Search

Your search keyword '"P. Guglielmelli"' showing total 1,006 results
Start Over Author "P. Guglielmelli"
1,006 results on '"P. Guglielmelli"'

1. P987: A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME

Author

E. Genovese, M. Mirabile, S. Rontauroli, S. Sartini, S. Fantini, L. Tavernari, M. Maccaferri, P. Guglielmelli, E. Bianchi, S. Parenti, C. Carretta, S. Mallia, S. Castellano, C. Colasante, M. Balliu, N. Bartalucci, R. Palmieri, T. Ottone, B. Mora, L. Potenza, F. Passamonti, M. T. Voso, M. Luppi, A. M. Vannucchi, E. Tagliafico, and R. Manfredini

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

2. P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

Author

B. Mora, P. Guglielmelli, A. Kuykendall, M. Maffioli, G. Rotunno, R. S. Komrokji, F. Palandri, J.-J. Kiladjian, A. Iurlo, G. Auteri, D. Cattaneo, V. De Stefano, S. Salmoiraghi, T. Devos, F. Cervantes, M. Merli, A. Campagna, G. Benevolo, M. Brociner, F. Albano, J. Gotlib, M. Caramella, M. Ruggeri, D. M. Ross, F. Orsini, C. Pessina, I. Colugnat, F. Pallotti, T. Barbui, L. Bertù, M. G. Della Porta, A. M. Vannucchi, and F. Passamonti

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

3. P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS

Author

S. Sartini, S. Fantini, S. Rontauroli, M. Mirabile, E. Bianchi, F. Badii, M. Maccaferri, P. Guglielmelli, T. Ottone, R. Palmieri, E. Genovese, C. Carretta, S. Parenti, S. Mallia, L. Tavernari, C. Salvadori, F. Gesullo, C. Maccari, M. Zizza, A. Grande, S. Salmoiraghi, B. Mora, L. Potenza, V. Rosti, F. Passamonti, A. Rambaldi, M. T. Voso, C. Mecucci, E. Tagliafico, M. Luppi, A. M. Vannucchi, and R. Manfredini

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

4. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19

Author

T. Barbui, A. Carobbio, A. Masciulli, A. Iurlo, M. A. Sobas, E. M. Elli, E. Rumi, V. De Stefano, F. Lunghi, M. Marchetti, R. Daffini, M. Gasior Kabat, B. Cuevas, M. L. Fox, M. M. Andrade Campos, F. Palandri, P. Guglielmelli, G. Benevolo, C. Harrison, M. A. Foncillas, M. Bonifacio, A. Alvarez-Larran, J.-J. Kiladjian, E. Bolanos Calderon, A. Patriarca, K. S. Quiroz Cervantes, M. Griesshammer, V. Garcia-Gutierrez, A. Marin Sanchez, E. Magro Mazo, M. Ruggeri, J. C. Hernandez-Boluda, S. Osorio, G. Carreno-Tarragona, M. Sagues Serrano, R. Kusec, B. Navas Elorza, A. Angona, B. Xicoy Cirici, E. Lopez Abadia, S. Koschmieder, E. Cichocka, A. Kulikowska de Nałęcz, M. Bellini, D. Cattaneo, C. Bucelli, F. Cavalca, O. Borsani, S. Betti, N. Curto-Garcia, S. Carbonell, L. Benajiba, A. Rambaldi, and A. M. Vannucchi

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

7. Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms

Author

Carretta, Chiara, Parenti, Sandra, Bertesi, Matteo, Rontauroli, Sebastiano, Badii, Filippo, Tavernari, Lara, Genovese, Elena, Malerba, Marica, Papa, Elisa, Sperduti, Samantha, Enzo, Elena, Mirabile, Margherita, Pedrazzi, Francesca, Neroni, Anita, Tombari, Camilla, Mora, Barbara, Maffioli, Margherita, Mondini, Marco, Brociner, Marco, Maccaferri, Monica, Tenedini, Elena, Martinelli, Silvia, Bartalucci, Niccolò, Bianchi, Elisa, Casarini, Livio, Potenza, Leonardo, Luppi, Mario, Tagliafico, Enrico, Guglielmelli, Paola, Simoni, Manuela, Passamonti, Francesco, Norfo, Ruggiero, Vannucchi, Alessandro Maria, and Manfredini, Rossella

Published
2024
Full Text
View/download PDF

8. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

Author

Kiladjian, Jean-Jacques, Marin, Francisca Ferrer, Al-Ali, Haifa Kathrin, Alvarez-Larrán, Alberto, Beggiato, Eloise, Bieniaszewska, Maria, Breccia, Massimo, Buxhofer-Ausch, Veronika, Cerna, Olga, Crisan, Ana-Manuela, Danaila, Catalin Doru, De Stefano, Valerio, Döhner, Konstanze, Empson, Victoria, Gora-Tybor, Joanna, Griesshammer, Martin, Grosicki, Sebastian, Guglielmelli, Paola, García-Gutierrez, Valentin, Heidel, Florian H., Illés, Arpád, Tomuleasa, Ciprian, James, Chloe, Koschmieder, Steffen, Krauth, Maria-Theresa, Krejcy, Kurt, Lazaroiu, Mihaela-Cornelia, Mayer, Jiri, Nagy, Zsolt György, Nicolini, Franck-Emmanuel, Palandri, Francesca, Pappa, Vassiliki, Reiter, Andreas Johannes, Sacha, Tomasz, Schlager, Stefanie, Schmidt, Stefan, Terpos, Evangelos, Unger, Martin, Wölfler, Albert, Cirici, Blanca Xicoy, and Klade, Christoph

Published
2024
Full Text
View/download PDF

9. Unveiling Chirality: Exploring Nature's Blueprint for Engineering Nanostructured Materials

Author

Guglielmelli, Alexa, Valente, Liliana, Palermo, Giovanna, and Strangi, Giuseppe

Subjects
Physics - Optics, Physics - Applied Physics
Abstract

Chirality, the property of asymmetry, is of great importance in biological and physical phenomena. This prospective offers an overview of the emerging field of chiral bioinspired plasmonics and metamaterials, aiming to uncover nature's blueprint for engineering nanostructured materials. These materials possess unique chiral structures, resulting in fascinating optical properties and finding applications in sensing, photonics, and catalysis. The first part of the prospective focuses on the design and fabrication of chiral metamaterials that mimic intricate structures found in biological systems. By employing self-assembly and nanofabrication techniques, researchers have achieved remarkable control over the response to light, opening up new avenues for manipulating light and controlling polarization. Chiral metamaterials hold significant promise for sensing applications, as they can selectively interact with chiral molecules, allowing for highly sensitive detection and identification. The second part delves into the field of plasmonics nanostructures, which mediate enantioselective recognition through optical chirality enhancement. Plasmonic nanostructures, capable of confining and manipulating light at the nanoscale, offer a platform for amplifying and controlling chirality-related phenomena. Integrating plasmonic nanostructures with chiral molecules presents unprecedented opportunities for chiral sensing, enantioselective catalysis, and optoelectronic devices. By combining the principles of chiral bioinspired plasmonics and metamaterials, researchers are poised to unlock new frontiers in designing and engineering nanostructured materials with tailored chiroptical properties.

Published
2023

12. Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting

Author

Gaia Ciolli, Matteo Piccini, Francesco Mannelli, Giacomo Gianfaldoni, Barbara Scappini, Laura Fasano, Francesca Crupi, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Chiara Maccari, Fiorenza I. Vanderwert, Paola Guglielmelli, and Alessandro M. Vannucchi

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2024
Full Text
View/download PDF

14. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes

Author

Barbui, Tiziano, Carobbio, Alessandra, De Stefano, Valerio, Alvarez-Larran, Alberto, Ghirardi, Arianna, Carioli, Greta, Fenili, Francesca, Rossi, Elena, Ciceri, Fabio, Bonifacio, Massimiliano, Iurlo, Alessandra, Palandri, Francesca, Benevolo, Giulia, Pane, Fabrizio, Ricco, Alessandra, Carli, Giuseppe, Caramella, Marianna, Rapezzi, Davide, Musolino, Caterina, Siragusa, Sergio, Rumi, Elisa, Patriarca, Andrea, Cascavilla, Nicola, Mora, Barbara, Cacciola, Emma, Calabresi, Laura, Loscocco, Giuseppe Gaetano, Guglielmelli, Paola, Gesullo, Francesca, Betti, Silvia, Ramundo, Francesco, Lunghi, Francesca, Scaffidi, Luigi, Bucelli, Cristina, Cattaneo, Daniele, Vianelli, Nicola, Bellini, Marta, Finazzi, Maria Chiara, Tognoni, Gianni, Rambaldi, Alessandro, and Vannucchi, Alessandro Maria

Published
2024
Full Text
View/download PDF

15. All-Optical tunability of metalenses infiltrated with liquid crystals

Author

Palermo, Giovanna, Lininger, Andrew, Guglielmelli, Alexa, Ricciardi, Loredana, Nicoletta, Giuseppe, De Luca, Antonio, Park, Joon-Suh, Lim, Soon Wei Daniel, Meretska, Maryna L., Capasso, Federico, and Strangi, Giuseppe

Subjects
Physics - Optics, Condensed Matter - Soft Condensed Matter
Abstract

Metasurfaces have been extensively engineered to produce a wide range of optical phenomena, allowing unprecedented control over the propagation of light. However, they are generally designed as single-purpose devices without a modifiable post-fabrication optical response, which can be a limitation to real-world applications. In this work, we report a nanostructured planar fused silica metalens permeated with a nematic liquid crystal (NLC) and gold nanoparticle solution. The physical properties of embedded NLCs can be manipulated with the application of external stimuli, enabling reconfigurable optical metasurfaces. We report all-optical, dynamic control of the metalens optical response resulting from thermo-plasmonic induced changes of the NLC solution associated with the nematic-isotropic phase transition. A continuous and reversible tuning of the metalens focal length is experimentally demonstrated, with a variation of 80 um (0.16% of the 5 cm nominal focal length) along the optical axis. This is achieved without direct mechanical or electrical manipulation of the device. The reconfigurable properties are compared with corroborating numerical simulations of the focal length shift and exhibit close correspondence., Comment: Main text

Published
2022
Full Text
View/download PDF

17. Restoring of Interhemispheric Symmetry in Patients With Stroke Following Bilateral or Unilateral Robot-Assisted Upper-Limb Rehabilitation: A Pilot Randomized Controlled Trial

Author

M. C. Mauro, A. Fasano, M. Germanotta, L. Cortellini, S. Insalaco, A. Pavan, A. Comanducci, E. Guglielmelli, and I. G. Aprile

Subjects
Stroke, quantitative electroencephalography (qEEG), robotics, rehabilitation, interhemispheric balance, brain symmetry index (BSI), Medical technology, R855-855.5, Therapeutics. Pharmacology, RM1-950
Abstract

Bilateral robotic rehabilitation has proven helpful in the recovery of upper limb motor function in patients with stroke, but its effects on the cortical reorganization mechanisms underlying recovery are still unclear. This pilot Randomized Controlled Trial (RCT) aimed to evaluate the effects on the interhemispheric balance of unilateral or bilateral robotic treatments in patients with subacute stroke, using Quantitative Electroencephalography (qEEG). 19 patients with ischemic stroke underwent a 30-session upper limb neurorehabilitation intervention using a bilateral upper limb exoskeleton. Each patient was randomly assigned to the bilateral (BG, n=10) or unilateral treatment group (UG, n=9). EEG evaluations were performed before (T0) and right after (T $0+\text {)}$ the first treatment session, after 30 treatment sessions (T1), and at 1-week follow-up (T2), in both eyes open and eyes closed conditions. From the acquired EEG data, the pairwise-derived Brain Symmetry Index (pdBSI) was computed. In addition, clinical evaluation was performed at T0 and T1 with validated clinical scales. After the treatment, a significant improvement in clinical and EEG evaluations was observed for both groups, but only the BG showed reduced pdBSI in delta and theta bands. In the cluster of sensorimotor channels, there was no significant difference between groups. The observed changes were not maintained at follow-up. No significant changes were observed in the pdBSI after a single rehabilitation session. Results suggest that balancing of interhemispheric symmetry comes along with a clinical improvement in the upper extremity and that the pdBSI can be used to investigate the mechanisms of neuronal plasticity involved in robotic rehabilitation after stroke.

Published
2024
Full Text
View/download PDF

18. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience

Author

Giuseppe G. Loscocco, Francesca Gesullo, Giulio Capecchi, Alessandro Atanasio, Chiara Maccari, Francesco Mannelli, Alessandro M. Vannucchi, and Paola Guglielmelli

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18–95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets ≥1000 × 109/L) in 16%, leukocytosis (leukocytes >11 × 109/L) in 16%, and at least one cardiovascular risk factor in 52% of cases. JAK2-mutated patients were older (median 62 years) and CALR-mutated and TN (53 years for both) younger (p

Published
2024
Full Text
View/download PDF

21. Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib

Author

Giacomo Coltro, Giulio Capecchi, Margherita Maffioli, Francesco Mannelli, Barbara Mora, Alessandro Atanasio, Alessandra Iurlo, Chiara Maccari, Mirko Farina, Elena Nacca, Marianna Caramella, Leonardo Signori, Miriam Borella, Lorenza Bertù, Maria Esposito, Paola Guglielmelli, Francesco Passamonti, and Alessandro Maria Vannucchi

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2024
Full Text
View/download PDF

22. Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model

Author

Bianchi, Elisa, Rontauroli, Sebastiano, Tavernari, Lara, Mirabile, Margherita, Pedrazzi, Francesca, Genovese, Elena, Sartini, Stefano, Dall’Ora, Massimiliano, Grisendi, Giulia, Fabbiani, Luca, Maccaferri, Monica, Carretta, Chiara, Parenti, Sandra, Fantini, Sebastian, Bartalucci, Niccolò, Calabresi, Laura, Balliu, Manjola, Guglielmelli, Paola, Potenza, Leonardo, Tagliafico, Enrico, Losi, Lorena, Dominici, Massimo, Luppi, Mario, Vannucchi, Alessandro Maria, and Manfredini, Rossella

Published
2023
Full Text
View/download PDF

24. Incidence of blast phase in myelofibrosis according to anemia severity

Author

Barbara Mora, Margherita Maffioli, Elisa Rumi, Paola Guglielmelli, Marianna Caramella, Andrew Kuykendall, Francesca Palandri, Alessandra Iurlo, Valerio De Stefano, Jean‐Jacques Kiladjian, Elena M. Elli, Nicola Polverelli, Jason Gotlib, Francesco Albano, Richard T. Silver, Giulia Benevolo, David M. Ross, Timothy Devos, Oscar Borsani, Tiziano Barbui, Matteo G. Della Porta, Lorenza Bertù, Rami Komrokji, Alessandro M. Vannucchi, and Francesco Passamonti

Subjects
acute myeloid leukemia, essential thrombocythemia, myelofibrosis, polycythemia vera, ruxolitinib, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract Myelofibrosis (MF) is a clonal malignancy frequently characterized by anemia and in 10%–20% of cases it can evolve into blast phase (BP). Anemia in MF is associated with reduced survival and ‐in primary MF‐ also with an increased probability of BP. Conventional treatments for anemia have limited effectiveness in MF. Within a dataset of 1752 MF subjects largely unexposed to ruxolitinib (RUX), BP incidence was 2.5% patients per year (p‐y). This rate reached respectively 4.3% and 4.5% p‐y in case of patients with common terminology criteria for adverse events (CTCAE) grade 3/4 and grade 2 anemia, respectively, that represented together 32% of the cohort. Among 273 MF cases treated with RUX, BP incidence was 2.89% p‐y and it reached 4.86% p‐y in subjects who started RUX with CTCAE grade 2 anemia (one third of total). Within patients with red blood cell transfusion‐dependency at 6 months of RUX (21% of the exposed), BP rate was 4.2% p‐y. Our study highlights a relevant incidence of BP in anemic MF patients, with a similar rate whether treated with or without RUX. These findings will help treating physicians to make decisions on the safety profile of innovative anemia treatments.

Published
2023
Full Text
View/download PDF

25. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project

Author

Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A. Palumbo, Francesco Mannelli, Valerio De Stefano, Marco Ruggeri, Elena M. Elli, Roberta Zanotti, Oscar Borsani, Irene Bertozzi, Andrea Duminuco, Silvia Betti, Giuseppe Carli, Fabrizio Cavalca, Ilaria Tanasi, Elisa Rumi, Maria L. Randi, Bruno Garibaldi, Giuseppe G. Loscocco, Paola Guglielmelli, and Alessandro M. Vannucchi

Subjects
efficacy, myelofibrosis, ruxolitinib, safety, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Incorporating real‐world data in the drug development process allows the improvement of health outcomes by providing better representation of actual patterns of drug safety and efficacy. Aims and Methods Here, we present the results of a retroprospective, observational real‐life study of 154 patients with myelofibrosis treated with ruxolitinib in a real‐life setting in seven Italian centers of the MYNERVA project. Results Median drug exposure was 29 (range, 3–98) months. Discontinuation rate was 27% after a median time of 13 (range, 3–61). While hematological toxicities were in line with previous findings, infections occurred frequently, representing a not negligible cause of discontinuation and death. Anemia, symptoms, and spleen responses were obtained at any time in 23%, 91%, and 68% of patients, respectively; most patients achieved their responses by week 24. Larger splenomegaly and delayed treatment initiation correlated with lower spleen response at 24 weeks. Spleen response was associated with a superior overall survival, regardless of DIPSS. Of interest, both achievement and loss of spleen response had prognostic implications. Discussion and Conclusion Overall, our findings provide insights on the efficacy and safety of ruxolitinib in a real‐world, multicenter cohort of Italian MF patients.

Published
2023
Full Text
View/download PDF

26. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis

Author

Francesco Mannelli, Francesca Crupi, Roberta Zanotti, Livio Pagano, Davide Rapezzi, Ilaria Tanasi, Marianna Criscuolo, Massimiliano Bonifacio, Alberto Fresa, Paola Guglielmelli, and Alessandro M. Vannucchi

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

In systemic mastocytosis, cytoreductive treatment is indicated for advanced systemic mastocytosis (AdvSM) variants. The treatment scenario is rapidly diversifying especially with the introduction of KIT tyrosine kinase inhibitors. Avapritinib is a second-generation potent and selective inhibitor of the mutant KIT D816V that, based on the results of pivotal clinical trials, was approved for the treatment of adults with AdvSM by the regulatory agencies US FDA and EMA. The present article reports the experience of treating SM patients with avapritinib in an Italian compassionate use program. The data from our case series confirm the drug as being active after multiple lines of treatment allowing rapid achievement of profound responses, making it also an effective bridging strategy to allogeneic transplant in eligible patients. However, the anticipated wider use of avapritinib in the near future will require careful monitoring of side effects, especially in heavily pretreated patients.

Published
2023
Full Text
View/download PDF

27. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis

Author

Paola Guglielmelli, Chiara Maccari, Benedetta Sordi, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giuseppe Gaetano Loscocco, Giada Rotunno, Eva Angori, Filippo C. Borri, Ayalew Tefferi, and Alessandro M. Vannucchi

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2023
Full Text
View/download PDF

28. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients

Author

Mora, Barbara, Guglielmelli, Paola, Kuykendall, Andrew, Rumi, Elisa, Maffioli, Margherita, Palandri, Francesca, De Stefano, Valerio, Caramella, Marianna, Salmoiraghi, Silvia, Kiladjian, Jean-Jacques, Gotlib, Jason, Iurlo, Alessandra, Cervantes, Francisco, Ruggeri, Marco, Silver, Richard T., Albano, Francesco, Benevolo, Giulia, Ross, David M., Della Porta, Matteo G., Devos, Timothy, Rotunno, Giada, Komrokji, Rami S., Casetti, Ilaria C., Merli, Michele, Brociner, Marco, Caramazza, Domenica, Auteri, Giuseppe, Barbui, Tiziano, Cattaneo, Daniele, Bertù, Lorenza, Arcaini, Luca, Vannucchi, Alessandro M., and Passamonti, Francesco

Published
2022
Full Text
View/download PDF

29. Breakthrough infections in MPN-COVID vaccinated patients

Author

Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreno-Tarragona, Andrea Patriarca, Haifa Kathrin Al-Ali, Maria Marcio Miguel Andrade-Campos, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro Mazo, Jean-Jacques Kiladjian, Estefanía Bolaños Calderón, Florian H. Heidel, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagues Serrano, Rajko Kusec, Blanca Xicoy Cirici, Margarita Guenova, Begona Navas Elorza, Anna Angona, Edyta Cichocka, Anna Kulikowska de Nałęcz, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, and Alessandro Maria Vannucchi

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2022
Full Text
View/download PDF

30. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Author

Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Greta Carioli, Alessandro Rambaldi, Maria Chiara Finazzi, Marta Bellini, Elisa Rumi, Daniele Vanni, Oscar Borsani, Francesco Passamonti, Barbara Mora, Marco Brociner, Paola Guglielmelli, Chiara Paoli, Alberto Alvarez-Larran, Ana Triguero, Marta Garrote, Helna Pettersson, Björn Andréasson, Giovanni Barosi, and Alessandro Maria Vannucchi

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2022
Full Text
View/download PDF

31. P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

Author

Francesco Mannelli, Matteo Piccini, Sara Bencini, Giacomo Gianfaldoni, Benedetta Peruzzi, Roberto Caporale, Barbara Scappini, Laura Fasano, Elisa Quinti, Gaia Ciolli, Andrea Pasquini, Francesca Crupi, Sofia Pilerci, Fabiana Pancani, Leonardo Signori, Danilo Tarantino, Chiara Maccari, Vivian Paradiso, Francesco Annunziato, Paola Guglielmelli, and Alessandro Maria Vannucchi

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

32. P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT

Author

Alessandra Carobbio, Alessandro Vannucchi, Valerio De Stefano, Arianna Ghirardi, Greta Carioli, Arianna Masciulli, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Carmela Mannarelli, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Francesca Gesullo, Silvia Betti, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi, and Tiziano Barbui

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

33. P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS

Author

Prithviraj Bose, Sanjay Mohan, Stephen Oh, Jason Gotlib, Ellen Ritchie, Taizo Shimomura, Haris Ali, Francoise Boyer, Paola Guglielmelli, Anthony M. Hunter, Betty Lamothe, Yi Cui, Francis Seguy, Amanda Mcbride, Francesca Palandri, Masahiro Takeuchi, and Jean-Jacques Kiladjian

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

34. Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia

Author

Francesco Mannelli, Matteo Piccini, Sara Bencini, Giacomo Gianfaldoni, Benedetta Peruzzi, Roberto Caporale, Barbara Scappini, Laura Fasano, Elisa Quinti, Gaia Ciolli, Andrea Pasquini, Francesca Crupi, Sofia Pilerci, Fabiana Pancani, Leonardo Signori, Danilo Tarantino, Chiara Maccari, Vivian Paradiso, Francesco Annunziato, Paola Guglielmelli, and Alessandro M. Vannucchi

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Measurable residual disease (MRD) is a powerful predictor of outcome in acute myeloid leukemia. In the early phases of treatment, MRD refines initial disease risk stratification and is used for the allocation to allogeneic transplant. Despite its well-established role, a relatively high fraction of patients eventually relapses albeit achieving MRDneg status. The aim of this work was to assess specifically the influence of baseline features and treatment intensity on the predictive value of an MRDneg status, particularly focusing on MRD2, measured after two consecutive chemotherapy cycles. Among baseline features, younger MRD2neg patients (

Published
2023
Full Text
View/download PDF

35. Cross section measurements of $^{155,157}$Gd(n,$\gamma$) induced by thermal and epithermal neutrons

Author

Mastromarco, M., Manna, A., Aberle, O., Amaducci, S., Andrzejewski, J., Audouin, L., Bacak, M., Balibrea, J., Barbagallo, M., Becvar, F., Berthoumieux, E., Billowes, J., Bosnar, D., Brown, A., Caamano, M., Calvino, F., Calviani, M., Cano-Ott, D., Cardella, R., Casanovas, A., Castelluccio, D. M., Cerutti, F., Chen, Y. H., Chiaveri, E., Clai, G., Colonna, N., Cortes, G., Cortes-Giraldo, M. A., Cosentino, L., Damone, L. A., Diakaki, M., Dietz, M., Domingo-Pardo, C., Dressler, R., Dupont, E., Duran, I., Fernandez-Domnguez, B., Ferrari, A., Ferreira, P., Finocchiaro, P., Furman, V., Gobel, K., Garca, A. R., Gawlik, A., Gilardoni, S., Glodariu, T., Goncalves, I. F., Gonzalez-Romero, E., Griesmayer, E., Guerrero, C., Guglielmelli, A., Gunsing, F., Harada, H., Heinitz, S., Heyse, J., Jenkins, D. G., Jericha, E., Kaeppeler, F., Kadi, Y., Kalamara, A., Kavrigin, P., Kimura, A., Kivel, N., Kokkoris, M., Krticka, M., Kurtulgil, D., Leal-Cidoncha, E., Lederer-Woods, C., Leeb, H., Lerendegui-Marco, J., Lonsdale, S. J., Macina, D., Marganiec, J., Martnez, T., Masi, A., Massimi, C., Mastinu, P., Maugeri, E. A., Mazzone, A., Mendoza, E., Mengoni, A., Milazzo, P. M., Mingrone, F., Musumarra, A., Negret, A., Nolte, R., Oprea, A., Patronis, N., Pavlik, A., Perkowski, J., Porras, I., Praena, J., Quesada, J. M., Radeck, D., Rauscher, T., Reifarth, R., Rocchi, F., Rubbia, C., Ryan, J. A., Sabate-Gilarte, M., Saxena, A., Schillebeeckx, P., Schumann, D., Sedyshev, P., Smith, A. G., Sosnin, N. V., Stamatopoulos, A., Tagliente, G., Tain, J. L., Tarifeno-Saldivia, A., Tassan-Got, L., Valenta, S., Vannini, G., Variale, V., Vaz, P., Ventura, A., Vlachoudis, V., Vlastou, R., Wallner, A., Warren, S., Weiss, C., Woods, P. J., Wright, T., and Zugec, P.

Subjects
Nuclear Experiment
Abstract

Neutron capture measurements on $^{155}$Gd and $^{157}$Gd were performed using the time-of-flight technique at the n\_TOF facility at CERN. Four samples in form of self-sustaining metallic discs isotopically enriched in $^{155}$Gd and $^{157}$Gd were used. The measurements were carried out at the experimental area (EAR1) at 185 m from the neutron source, with an array of 4 C$_6$D$_6$ liquid scintillation detectors. The capture cross sections of $^{155}$Gd and $^{157}$Gd at neutron kinetic energy of 0.0253 eV have been estimated to be 62.2(2.2) kb and 239.8(9.3) kb, respectively, thus up to 6\% different relative to the ones reported in the nuclear data libraries. A resonance shape analysis has been performed in the resolved resonance region up to 180 eV and 300 eV, respectively, in average resonance parameters have been found in good agreement with evaluations. Above these energies the observed resonance-like structures in the cross section have been tentatively characterised in terms of resonance energy and area up to 1 keV.

Published
2018
Full Text
View/download PDF

37. Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance

Author

Massimo Breccia, Francesca Palandri, Paola Guglielmelli, Giuseppe Alberto Palumbo, Alessandra Malato, Francesco Mendicino, Alessandra Ricco, Emanuela Sant’Antonio, Mario Tiribelli, and Alessandra Iurlo

Subjects
anemia, infection, intolerance, myelofibrosis, non-melanoma skin cancer, resistance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptoms responses, improved quality of life, and overall survival. Despite this, several unmet needs remain, including the absence of resistance criteria, suboptimal response, the timing of allogeneic transplant, and the management of patients in case of intolerance. Here, we report the results of the second survey led by the “MPN Lab” collaboration, which aimed to report physicians’ perspectives on these topics. As in our first survey, physicians were selected throughout Italy, and we included those with extensive experience in treating myeloproliferative neoplasms and those with less experience representing clinical practice in the real world. The results presented here, summarized using descriptive analyses, highlight the need for a clear definition of response to ruxolitinib as well as recommendations to guide the management of ruxolitinib under specific conditions including anemia, thrombocytopenia, infections, and non-melanoma skin cancers.

Published
2022
Full Text
View/download PDF

39. Second versus first wave of COVID-19 in patients with MPN

Author

Barbui, Tiziano, Iurlo, Alessandra, Masciulli, Arianna, Carobbio, Alessandra, Ghirardi, Arianna, Carioli, Greta, Sobas, Marta Anna, Elli, Elena Maria, Rumi, Elisa, De Stefano, Valerio, Lunghi, Francesca, Marchetti, Monia, Daffini, Rosa, Gasior Kabat, Mercedes, Cuevas, Beatriz, Fox, Maria Laura, Andrade-Campos, Marcio Miguel, Palandri, Francesca, Guglielmelli, Paola, Benevolo, Giulia, Harrison, Claire, Foncillas, Maria Angeles, Bonifacio, Massimiliano, Alvarez-Larran, Alberto, Kiladjian, Jean-Jacques, Bolaños Calderón, Estefanía, Patriarca, Andrea, Quiroz Cervantes, Keina, Griessammer, Martin, Garcia-Gutierrez, Valentin, Marin Sanchez, Alberto, Magro Mazo, Elena, Ruggeri, Marco, Hernandez-Boluda, Juan Carlos, Osorio, Santiago, Carreno-Tarragona, Gonzalo, Sagues Serrano, Miguel, Kusec, Rajko, Navas Elorza, Begona, Angona, Anna, Xicoy Cirici, Blanca, Lopez Abadia, Emma, Koschmieder, Steffen, Cattaneo, Daniele, Bucelli, Cristina, Cichocka, Edyta, Masternak Kulikowska de Nałęcz, Anna, Cavalca, Fabrizio, Borsani, Oscar, Betti, Silvia, Benajiba, Lina, Bellini, Marta, Curto-Garcia, Natalia, Rambaldi, Alessandro, and Vannucchi, Alessandro Maria

Published
2022
Full Text
View/download PDF

42. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

Author

Alessandra Carobbio, Alessandro Maria Vannucchi, Valerio De Stefano, Arianna Masciulli, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Francesco Ramundo, Elena Rossi, Yogendra Kanthi, Ayalew Tefferi, and Tiziano Barbui

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis, respectively. Absolute counts of total leukocytes, neutrophils, lymphocytes, platelets, and the NLR were tested by generalized additive models (GAM) to evaluate their trend in continuous scale of thrombotic risk. Only for venous thrombosis, we showed that baseline absolute neutrophil and lymphocyte counts were on average respectively higher (median: 6.8 × 109/L, p = 0.002) and lower (median: 1.4 × 109/L, p = 0.001), leading to increased NLR values (median: 5.1, p = 0.002). In multivariate analysis, the risk of venous thrombosis was independently associated with previous venous events (HR = 5.48, p ≤ 0.001) and NLR values ≥5 (HR = 2.13, p = 0.001). Moreover, the relative risk in both low- and high-standard risk groups was almost doubled in the presence of NLR ≥ 5. These findings were validated in two Italian independent external cohorts (Florence, n = 282 and Rome, n = 175) of contemporary PV patients. Our data support recent experimental work that venous thrombosis is controlled by innate immune cells and highlight that NLR is an inexpensive and easily accessible prognostic biomarker of venous thrombosis.

Published
2022
Full Text
View/download PDF

43. A parallel classification strategy to simultaneous control elbow, wrist, and hand movements

Author

Francesca Leone, Cosimo Gentile, Francesca Cordella, Emanuele Gruppioni, Eugenio Guglielmelli, and Loredana Zollo

Subjects
Upper limb, Prosthetic control, Real-time and offline performance, Multi-DoFs control, Pattern recognition, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Abstract Background In the field of myoelectric control systems, pattern recognition (PR) algorithms have become always more interesting for predicting complex electromyography patterns involving movements with more than 2 Degrees of Freedom (DoFs). The majority of classification strategies, used for the prosthetic control, are based on single, hierarchical and parallel linear discriminant analysis (LDA) classifiers able to discriminate up to 19 wrist/hand gestures (in the 3-DoFs case), considering both combined and discrete motions. However, these strategies were introduced to simultaneously classify only 2 DoFs and their use is limited by the lack of online performance measures. This study introduces a novel classification strategy based on the Logistic Regression (LR) algorithm with regularization parameter to provide simultaneous classification of 3 DoFs motion classes. Methods The parallel PR-based strategy was tested on 15 healthy subjects, by using only six surface EMG sensors. Twenty-seven discrete and complex elbow, hand and wrist motions were classified by keeping the number of electromyographic (EMG) electrodes to a bare minimum and the classification error rate under 10 %. To this purpose, the parallel classification strategy was implemented by using three classifiers one for each DoF: the “Elbow classifier”, the “Wrist classifier”, and the “Hand classifier” provided the simultaneous control of the elbow, hand, and wrist joints, respectively. Results Both the offline and real-time performance metrics were evaluated and compared with the LDA parallel classification results. The real-time recognition results were statistically better with the LR classifier with respect to the LDA classifier, for all motion classes (elbow, hand and wrist). Conclusions In this paper, a novel parallel PR-based strategy was proposed for classifying up to 3 DoFs: three joint classifiers were employed simultaneously for classifying 27 motion classes related to the elbow, wrist, and hand and promising results were obtained.

Published
2022
Full Text
View/download PDF

44. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

Author

Paola Guglielmelli, Giuseppe G. Loscocco, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Patrizia Chiusolo, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, and Alessandro M. Vannucchi

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality. In this regard, the impact of JAK2V617F variant allele frequency (VAF) is still debated. The purpose of the current study was to analyze the impact of JAK2V617F VAF in the context of other established risk factors for thrombosis in a total of 865 2016 WHO-defined PV patients utilizing two independent cohorts: University of Florence (n = 576) as a training cohort and Policlinico Gemelli, Catholic University, Rome (n = 289) as a validation cohort. In the training cohort VT free-survival was significantly shorter in the presence of a JAK2V617F VAF > 50% (HR 4; p 50% (HR 3.8, p = 0.001) and previous VT (HR 2.2; p = 0.04) as independent risk factors for future VT whereas diabetes (HR 2.4; p = 0.02), hyperlipidemia (HR 2.3; p = 0.01) and previous AT (HR 2; p = 0.04) were independent risk factors for future AT. Similarly, JAK2V617F VAF > 50% (HR 2.4; p = 0.01) and previous VT (HR 2.8; p = 0.005) were confirmed as independent predictors of future VT in the validation cohort. Impact of JAK2V617F VAF > 50% on VT was particularly significant in conventional low-risk patients, both in Florence (HR 10.6, p = 0.005) and Rome cohort (HR 4; p = 0.02). In conclusion, we identified JAK2V617F VAF > 50% as an independent strong predictor of VT, supporting that AT and VT are different entities which might require distinct management.

Published
2021
Full Text
View/download PDF

45. Breakthrough infections in MPN-COVID vaccinated patients

Author

Barbui, Tiziano, Carobbio, Alessandra, Ghirardi, Arianna, Iurlo, Alessandra, De Stefano, Valerio, Sobas, Marta Anna, Rumi, Elisa, Elli, Elena Maria, Lunghi, Francesca, Gasior Kabat, Mercedes, Cuevas, Beatriz, Guglielmelli, Paola, Bonifacio, Massimiliano, Marchetti, Monia, Alvarez-Larran, Alberto, Fox, Laura, Bellini, Marta, Daffini, Rosa, Benevolo, Giulia, Carreno-Tarragona, Gonzalo, Patriarca, Andrea, Al-Ali, Haifa Kathrin, Andrade-Campos, Maria Marcio Miguel, Palandri, Francesca, Harrison, Claire, Foncillas, Maria Angeles, Osorio, Santiago, Koschmieder, Steffen, Magro Mazo, Elena, Kiladjian, Jean-Jacques, Bolaños Calderón, Estefanía, Heidel, Florian H., Quiroz Cervantes, Keina, Griesshammer, Martin, Garcia-Gutierrez, Valentin, Sanchez, Alberto Marin, Hernandez-Boluda, Juan Carlos, Lopez Abadia, Emma, Carli, Giuseppe, Sagues Serrano, Miguel, Kusec, Rajko, Xicoy Cirici, Blanca, Guenova, Margarita, Navas Elorza, Begona, Angona, Anna, Cichocka, Edyta, Kulikowska de Nałęcz, Anna, Cattaneo, Daniele, Bucelli, Cristina, Betti, Silvia, Borsani, Oscar, Cavalca, Fabrizio, Carbonell, Sara, Curto-Garcia, Natalia, Benajiba, Lina, Rambaldi, Alessandro, and Vannucchi, Alessandro Maria

Published
2022
Full Text
View/download PDF

46. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Author

Barbui, Tiziano, Ghirardi, Arianna, Carobbio, Alessandra, Masciulli, Arianna, Carioli, Greta, Rambaldi, Alessandro, Finazzi, Maria Chiara, Bellini, Marta, Rumi, Elisa, Vanni, Daniele, Borsani, Oscar, Passamonti, Francesco, Mora, Barbara, Brociner, Marco, Guglielmelli, Paola, Paoli, Chiara, Alvarez-Larran, Alberto, Triguero, Ana, Garrote, Marta, Pettersson, Helna, Andréasson, Björn, Barosi, Giovanni, and Vannucchi, Alessandro Maria

Published
2022
Full Text
View/download PDF

47. Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2

Author

Simone Romagnoli, Niccolò Bartalucci, Francesca Gesullo, Manjola Balliu, Stefania Bonifacio, Anair Graciela Lema Fernandez, Francesco Mannelli, Davide Bolognini, Elisabetta Pelo, Cristina Mecucci, Paola Guglielmelli, and Alessandro Maria Vannucchi

Subjects
Primary eosinophilic disorders, Nanopore sequencing, PDGFRα, PDGFRβ, FGFR1, Therapeutics. Pharmacology, RM1-950
Abstract

Abstract Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 represent the biomarkers of WHO-defined “myeloid and lymphoid neoplasms with eosinophilia”. The heterogeneous nature of genomic aberrations and the promiscuity of fusion partners, may limit the diagnostic accuracy of current cytogenetics approaches. To address such technical challenges, we exploited a nanopore-based sequencing assay to screen patients with primary Eosinophilia. The comprehensive sequencing approach described here enables the identification of genomic fusion in 60 h, starting from DNA purified from whole blood.

Published
2021
Full Text
View/download PDF

48. Long-term follow-up of recovered MPN patients with COVID-19

Author

Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Giuseppe Rossi, Claire Harrison, Alberto Alvarez-Larran, Elena Maria Elli, Jean-Jaques Kiladjian, Mercedes Gasior Kabat, Alberto Marin Sanchez, Francesca Palandri, Marcio Miguel Andrade-Campos, Alessandro Maria Vannucchi, Gonzalo Carreno-Tarragona, Petros Papadopoulos, Keina Quiroz Cervantes, Maria Angeles Foncillas, Maria Laura Fox, Miguel Sagues Serrano, Elisa Rumi, Santiago Osorio, Giulia Benevolo, Andrea Patriarca, Begona Navas Elorza, Valentin Garcia-Gutierrez, Elena Magro Mazo, Francesca Lunghi, Massimiliano Bonifacio, Valerio De Stefano, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Anna Angona, Blanca Xicoy Cirici, Marco Ruggeri, Steffen Koschmieder, Marta Anna Sobas, Beatriz Cuevas, Daniele Cattaneo, Rosa Daffini, Marta Bellini, Natalia Curto-Garcia, Marta Garrote, Fabrizio Cavalca, Lina Benajiba, Beatriz Bellosillo, Paola Guglielmelli, Oscar Borsani, Silvia Betti, Silvia Salmoiraghi, and Alessandro Rambaldi

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2021
Full Text
View/download PDF

50. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Author

Tefferi, Ayalew, Barosi, Giovanni, Passamonti, Francesco, Hernandez-Boluda, Juan-Carlos, Bose, Prithviraj, Döhner, Konstanze, Ellis, Martin, Gangat, Naseema, Garcia, Jacqueline S., Gisslinger, Heinz, Gotlib, Jason, Guglielmelli, Paola, Gupta, Vikas, Harrison, Claire, Hexner, Elizabeth O., Hobbs, Gabriela S., Kiladjian, Jean-Jacques, Koschmieder, Steffen, Kroger, Nicolaus, Kuykendall, Andrew T., Loscocco, Giuseppe G., Mascarenhas, John, Masarova, Lucia, Mesa, Ruben, Mora, Barbara, Odenike, Olatoyosi, Oh, Stephen T., Pardanani, Animesh, Patel, Anand, Pemmaraju, Naveen, Rambaldi, Alessandro, Rampal, Raajit, Sirhan, Shireen, Szuber, Natasha, Talpaz, Moshe, Vachhani, Pankit J., Vannucchi, Alessandro M., and Barbui, Tiziano

Abstract

•An international panel of 38 experts and clinical trialists in MF participated in the preparation of the current document.•New definitions of transfusion status, gender-specific hemoglobin thresholds, and criteria for major and minor responses are submitted.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results